

#### Steady performance; maintain "Tactical BUY"

Bharat Electronics (BEL) reported strong 2QFY23 results broadly inline estimates. Revenue came in at INR 3946 cr, +7.8% YoY/+26.8% QoQ with EBITDA margin of 21.7% (vs 23.4% YoY and 16.5% QoQ). 2QFY23 margin is slightly lower than to margins profile in 2Q's of pre-pandemic (for e.g. 24% in 2QFY18, 25.3% in 2QFY19 and 19.9% in 2QFY20. PAT came at INR 611 cr, -0.3% YoY/+41.6% QoQ, driven by better revenues and operating leverage. Order book at the end of 1QFY23 is INR 52,795 Cr, implying that new order intake in the quarter was quite weak at INR 1,370 Cr (slightly better than 1QFY23 order intake). We believe BEL will regain and sustain double digit revenue growth in FY23-24. We expect the company to deliver 21%/24% revenues/PAT CAGR over FY22-24E. Using 26x PE multiple (largely inline current trailing multiples), we raise target price to INR 130 (at 26x FY24 earnings).

### Strong order book to drive revenue growth; Addition of INR 8,060 cr order from Triton Electric

BEL has a strong order book position of INR 52,795 Cr. In Oct-2022, BEL signed INR 8,060 cr contract with Triton Electric vehicle for supply of battery packs for electric trucks. This contract is not reflected in the order book, and adjusting for it the order book would be INR 60,855 cr. Triton contract is executable over CY23 & CY24.

#### Moderation in book to bill ratio along expected lines

Book-to-bill ratio stands at 3.13x (LTM basis) compared to 3.8x after 4QFY22 and 3.3x after 1QFY23, Moderation in book to bill ratio is along expected lines as debottlenecking (from normalcy in execution and easing of supply chain) will lead to normalized/quicker order-to-revenue conversion and seasonality in order intake (whereby 1H is usually softer).

#### **Valuation**

We believe BEL will regain and sustain double digit revenue growth in FY23-24, based on strong order book position, strong project line-ups, and easing of supply chains. Order book stands at INR 52,795 Cr and after adjusting for Triton Electric vehicle contract of INR 8,060 Cr, order book would be INR 60,855 cr. With strong order book in hand and parallel execution capability for multiple platforms, BEL has a strong P/L growth visibility. Further, it is emerging as a key beneficiary of increase in defence capital expenditure. Rising local player allocation & Gol's focus on exports in defence are material growth tailwinds for the company. We expect BEL's top-line growth to improve for FY23/24 given better new order growth in past two years & normalisation in supply chain. We raise our FY24E earnings by ~12% and using 26x PE multiple (largely inline current trailing multiples), we raise target price to INR 130 (at 26x FY24 earnings).

Year to March (INR Cr)	Q2FY23	Q2FY22	% Change	Q1FY23	% Change
Net Revenue	3,946	3,661	7.8	3,113	26.8
EBITDA	856	857	-0.1	514	66.7
Adjusted Profit	611	613	-0.3	432	41.6
Diluted EPS (INR)	0.8	0.8	-0.3	0.6	41.6

## Sushil Sharma Research Analyst sushilk.sharma@edelweiss.in

CMP: INR 106 Rating: Buy

Target price: INR 130

Upside: 23%

Date: October 31, 2022

Bloomberg:	BHE:IN
52-week range (INR):	61/ 115
M-cap (INR cr):	77,009
Promoter holding (%)	51.14



Steady performance; maintain "Tactical BUY"

Year to March	Q2FY23	Q2FY22	YoY (%)	Q1FY23	QoQ (%)	3Y CAGR	H1FY23	H1FY22	YoY (%)	3Y CAGR	FY22	FY23E	FY24E
Revenues	3,946	3,661	7.8	3,113	26.8	12.9	7,059	5,295	33.3	13.4	15,314	18,080	22,336
Materials cost	2,238	2,067	8.3	1,809	23.8		4,047	3,021	33.9		8,903	9,836	12,061
Staff costs	596	533	11.8	576	3.3		1,172	1,028	14.0		2,109	2,640	3,261
Other expenses	256	205	25.2	215	19.5		471	327	44.0		993	1,501	1,899
Total expenditure	3,090	2,804	10.2	2,599	18.9		5,689	4,376	30.0		12,005	13,976	17,221
EBITDA	856	857	-0.1	514	66.7	16.2	1,369	919	48.9	15.3	3,309	4,104	5,115
Interest	2	1		1			3	1			5	7	7
Depreciation	104	94	10.7	94	10.7		198	186	6.4		380	435	441
Other income	75	66	13.9	160	-53.0		235	111	112.4		234	350	314
Add: Exceptional items											-	-	-
PBT	825	828	-0.3	578	42.7		1,403	843	66.4		3,158	4,012	4,980
Tax	214	215	-0.6	147	45.8		360	219	64.5		809	1,043	1,395
Reported profit	611	613	-0.3	432	41.6		1,043	624	67.1		2,349	2,969	3,586
Adjusted profit	611	613	-0.3	432	41.6	21.6	1,043	624	67.1	24.2	2,349	2,969	3,586
Equity capital	731	731		731			731	731			244	244	244
No. of shares (Cr)	731	731		731			731	731			731	731	731
Adj. diluted EPS (INR)	1	1		1			1	1			3	4	5
As % of net revenues													
Raw material	57	57	0.3	58			57	57	0.3		58	54	54
Staff expenses	15	15		19			17	19			14	15	15
Other expenses	7	6	0.9	7			7	6	0.5		7	8	9
EBITDA	22	23	-1.7	17			19	17	2.0		22	23	23
Adjusted profit	16	17		14		1.6	15	12			15	16	16



Steady performance; maintain "Tactical BUY"

#### **Financials**

**Income Statement (INR Cr)** 

mediae statement (mix cr)				
Year to March	FY21A	FY22A	FY23E	FY24E
Total operating income	14,064	15,314	18,080	22,336
Gross profit	6,236	6,411	8,245	10,275
Employee costs	1,941	2,109	2,640	3,261
Other expenses	1,114	993	1,501	1,899
EBITDA	3,181	3,309	4,104	5,115
Depreciation	366	380	435	441
Less: Interest expense	6	5	7	7
Add: Other income	126	234	350	314
Profit before tax	2,935	3,158	4,012	4,980
Prov for tax	869	809	1,043	1,395
Less: Other adj	-	-	-	-
Reported profit	2,065	2,349	2,969	3,586
Less: Excp.item (net)	-	-	-	-
Adjusted profit	2,065	2,349	2,969	3,586
Diluted shares o/s	244	244	244	244
Adjusted diluted EPS	9	10	12	15
DPS (INR)	12	14	6	7
Tax rate (%)	30	26	26	28

**Important Ratios (%)** 

Year to March	FY21A	FY22A	FY23E	FY24E
COGS (% of rev)	55.7	58.1	54.4	54
Employee cost (% of rev)	13.8	13.8	14.6	14.6
Other exp (% of rev)	7.9	6.5	8.3	8.5
EBITDA margin (%)	22.6	21.6	22.7	22.9
Net profit margin (%)	14.7	15.3	16.4	16.1
Revenue growth (% YoY)	9.6	8.9	18.5	23.8
EBITDA growth (% YoY)	16.5	4	24	24.6
Adj. profit growth (%)	15.1	13.7	26.4	20.8

#### **Valuation Metrics**

Year to March	FY21A	FY22A	FY23E	FY24E
Diluted P/E (x)	12.7	11.2	8.9	7.3
Price/BV (x)	2.4	2.2	1.9	1.7
EV/EBITDA (x)	7.3	7.6	5.1	3.7
Dividend yield (%)	11.1	12.5	5.1	6.1



### Steady performance; maintain "Tactical BUY"

<b>Balance Sheet</b>	(INR Cr	)
----------------------	---------	---

Year to March	FY21A	FY22A	FY23E	FY24E
Share capital	244	244	244	244
Reserves	10,564	11,741	13,374	15,346
Shareholders funds	10,808	11,984	13,617	15,589
Minority interest	-	-	-	-
Borrowings	-	-	-	-
Trade payables	4,253	4,325	4,042	5,287
Other liabs & prov	12,048	14,587	16,986	18,891
Total liabilities	28,590	32,829	36,579	41,701
Net block	2,423	2,455	2,522	2,585
Intangible assets	57	69	71	73
Capital WIP	736	859	859	859
Total fixed assets	3,216	3,383	3,452	3,517
Non current inv	1,367	1,584	1,584	1,584
Cash/cash equivalent	3,016	1,239	5,225	7,617
Sundry debtors	8,609	12,467	10,402	11,627
Loans & advances	-	-	-	-
Other assets	12,382	14,156	15,915	17,356
Total assets	28,590	32,829	36,579	41,701

#### Free Cash Flow (INR Cr)

rice easi rion (iiii ei)				
Year to March	FY21A	FY22A	FY23E	FY24E
Reported profit	2,065	2,349	2,969	3,586
Add: Depreciation	366	380	435	441
Interest (net of tax)	4	4	5	5
Others	408	-121	-355	-319
Less: Changes in WC	2,260	1,550	2,423	485
Operating cash flow	5,104	4,161	5,477	4,198
Less: Capex	466	546	505	505
Free cash flow	4,637	3,615	4,972	3,693

#### **Key Ratios**

Year to March	FY21A	FY22A	FY23E	FY24E
RoE (%)	20	20.6	23.2	24.6
RoCE (%)	28.5	27.8	31.4	34.2
Inventory days	208	216	223	200
Receivable days	203	251	231	180
Payable days	175	176	155	141
Working cap (% sales)	30.6	47.1	26.2	19
Gross debt/equity (x)	0	0	0	0
Net debt/equity (x)	-0.3	-0.1	-0.4	-0.5
Interest coverage (x)	463	603.9	521.7	633

Year to March	FY21A	FY22A	FY23E	FY24E
EPS growth (%)	15.1	13.7	26.4	20.8
RoE (%)	20	20.6	23.2	24.6
EBITDA growth (%)	16.5	4	24	24.6
Payout ratio (%)	141.6	140	45	45



Steady performance; maintain "Tactical BUY"

### The Team

Analysts	Sector
Vinay Khattar	Head of Research
Sandeep Raina	Head - Fundamental
Sagar Doshi	Head - Trading
Arun Jain	Practice Head - Trading
Kavita Chacko	Chief Economist
Amit Agarwal	Infra, Real Estate, Hotels
Praveen Sahay	Consumer Durables, Building materials, Healthcare
	services, Hospitality
Kapil Jagasia	Consumption, Textile, QSR, Retail
Raj Jha	BFSI, NBFC
Jigar Jani	BFSI, NBFC
Ranvir Singh	Pharma, Chemicals
Himanshu Yadav	Cement, Logistics, Mid-caps
Sushil Sharma	IT, Capital Goods, Defence
Tushar Chaudhari	Metals, Mid- Caps
Parag Shah	Technical Analyst
Ankit Narshana	Option Trader
Nikhil Shetty	Mid Caps

Sales Team	Location
Sharad Tripathi	Mumbai
Ketan Malkan	Mumbai
Vikas Sharma	Bengaluru
Abhishek Agarwal	Kolkata
Vivek Khanna	Delhi

### **Coverage Universe**

Sr. No	Coverage
1	Aditya Birla Fashion & Retail Ltd
2	Aegis Logistics Ltd
3	Amber Enterprises India Ltd
4	Astral Ltd
5	Balaji Amines Ltd
6	Bata India Ltd
7	Birla Corporation Limited
8	Can Fin Homes Ltd
9	Century Plyboards India Ltd
10	Cholamandalam Inv and Finance Ltd
11	City Union Bank Ltd
12	CreditAccess Grameen Ltd
13	Crompton Greaves Consumer Electricals Ltd
14	CSB Bank Ltd
15	Deepak Nitrite Ltd
16	Easy Trip Planner Ltd
17	Escorts Ltd
18	Finolex Industries Ltd
19	Home First Finance Company India Ltd
20	Indo Count Industries Ltd
21	K P R Mill Ltd
22	KNR Constructions Ltd
23	Krishna Institute of Medical Sciences Ltd
24	Lumax Industries. Ltd
25	Metropolis Healthcare Ltd
26	Minda Industries Ltd
27	Motherson Sumi Ltd
28	Navin Fluorine International Ltd
29	Neogen Chemicals Ltd
30	Newgen Software Technologies Ltd
31	Orient Electric Ltd
32	PSP Projects Ltd
33	Rossari Biotech Ltd
34	Shriram Transport Finance Company Ltd
35	SRF Ltd
36	Vinati Organics Ltd
37	Voltas Ltd
38	Westlife Development Ltd
39	Zydus Wellness Ltd
40	Tarsons Products Ltd
41	MTAR Technologies Ltd.
42	S J S Enterprises Ltd

Sr. No	Tactical Buy
1	ACC Ltd
2	Ajanta Pharma Ltd
3	Ambuja Cements Ltd
4	Ashok Leyland Ltd
	Axis Bank Ltd
6	Bharat Electronics Ltd
7	
	Brigade Enterprises Ltd  DLF Ltd
8	
9	eClerx Services Ltd
10	Globus Spitits Ltd
11	GNA Axles Ltd
12	HDFC Life Insurance Co. Ltd
13	ICICI Bank Ltd
14	Indusind Bank Ltd
15	Jamna Auto Industries Ltd
16	JK Cement Ltd
17	Larsen & Toubro Ltd
18	Mahindra and Mahindra Ltd
19	Max Financial Services Ltd
20	Max Healthcare Institute Ltd
21	PNC Infratech Ltd
22	RBL Bank Ltd
23	Sun Pharma Ltd
24	TechMahindra Ltd
25	Ultratech Cement Ltd
26	Elecon Engineering Company Ltd
27	Kennametal India Ltd



**Edelweiss Broking Limited**, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirol Road, Kurla(W) Board: (91-22) 4272 2200

**Vinay Khattar** 

**Head Research** 

vinay.khattar@edelweiss.in



### **Disclaimer**

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000000172.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231 (Member of NSE, BSE, MCX and NCDEX). EBL CIN: U65100GJ2008PLC077462. Research services offered by Edelweiss Broking Ltd. under SEBI Registration No. INH000000172. Depository Participant SEBI Registration No.: IN-DP-656-2021 with NSDL having DP ID: IN302201 & IN303719 and with CDSL having DP ID: 12032300. Investor grievance resolution team: 040-41151621; Email ID: Helpdesk@edelweiss.in (for trading related) and dpservicesebl@edelweiss.in (for demat related). Name of the Compliance Officer for Trading & DP - Mr. Pranav Tanna, Email IDs: complianceofficer.ebl@edelweissfin.com / ebl.dpcompliance@edelweissfin.com. Edelweiss Broking Ltd. also acts in the capacity of distributor for Products such as OFS, Mutual Funds and NCD etc

Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098, Contact 18001023335 / (022)-42722200 / 022-40094279.

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.INH000000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of EBL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of EBL and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have renewed compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No EBL has financial interest in the subject companies: No





EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years.

A graph of daily closing prices of the securities is also available at www.nseindia.com

#### Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

#### Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

#### Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

#### Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

#### Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.